Track: PWBD
Michelle Lavin, MB BCh BAO, PhD, FRCPath (she/her/hers)
Consultant Haematologist
National Coagulation Centre, St. James's Hospital
Dublin, Ireland
Elizabeth Clearfield, MHS (she/her/hers)
Senior Research Manager
Institute for Policy Advancement Limited
Baltimore, United States
Paula James, MD, FRCPC (she/her/hers)
Professor, Department of Medicine
Queen's University
Kingston, Canada
Mark Skinner, JD (he/him/his)
President and CEO
Institute for Policy Advancement Ltd
Washington, United States
Treatment for von Willebrand Disease (VWD) lags behind hemophilia, as huge advances have come to the market. It’s critical to understand what is important to people living with VWD, taking inventory of what we know, what we have done and what needs to be done to advance treatment for this population. You will learn how coreVWD can be a catalyst to focus patient relevant outcomes and the needed research so we can harmonize, compare and measure data across studies.
Chair: Michelle Lavin, MB BCh BAO, PhD, FRCPath (she/her/hers) – National Coagulation Centre, St. James's Hospital
Speaker: Mark W. Skinner, JD (he/him/his) – Institute for Policy Advancement Ltd
Speaker: Elizabeth Clearfield, MHS (she/her/hers) – Institute for Policy Advancement Limited
Speaker: Paula James, MD, FRCPC (she/her/hers) – Queen's University